| Abstract | Murine plasmacytomas show a striking dependence on interleukin 6 (IL-6) for their growth in vitro. Here, we present evidence suggesting that IL-6 also plays an essential role in the in vivo development of these tumors. This conclusion is based on the finding that the tumorigenicity of an IL-6-dependent plasmacytoma cell line was increased approximately 100-fold on transfection with an IL-6 expression vector, whereas it was inhibited in animals treated with monoclonal antibodies capable of blocking the binding of IL-6 to its receptor. Injection of these antibodies 1 d before tumor challenge protected greater than 50% of the mice and retarded tumor growth in all animals. Tumors arising in antibody-treated mice retained their IL-6 dependence in vitro, suggesting that the level of protection could be improved if stronger IL-6 antagonists were available. |
| Authors | A Vink, P Coulie, G Warnier, J C Renauld, M Stevens, D Donckers, J Van Snick
(Affiliation: Ludwig Institute for Cancer Research, Brussels, Belgium.)
|
| Journal | The Journal of experimental medicine
(J Exp Med)
Vol. 172
Issue 3
Pg. 997-1000
(Sep 1 1990)
ISSN: 0022-1007 UNITED STATES |
| PMID | 2388041
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Antibodies, Monoclonal
- Interleukin-6
- Receptors, Immunologic
- Receptors, Interleukin-6
|
| Topics |
- Animals
- Antibodies, Monoclonal
(therapeutic use)
- Cell Line
- Immunotherapy
- Interleukin-6
(genetics, immunology, physiology)
- Mice
- Mice, Inbred BALB C
- Plasmacytoma
(immunology, pathology, therapy)
- Receptors, Immunologic
(immunology)
- Receptors, Interleukin-6
- Transfection
|
